RCS - OptiBiotix Health - Slimbiome study results

OptiBiotix HealthAnnouncement

20/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240620:nRST1098Ta&default-theme=true

RNS Number : 1098T  OptiBiotix Health PLC  20 June 2024

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

20 June 2024

Slimbiome study results

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease, diabetes and skincare,
notes the latest results from the human studies carried out at Roehampton
University, London on OptiBiotix's SlimBiome®.

 

Study outcomes, awaiting publication, suggested SlimBiome® intake had a major
impact on insulin response combined with significantly lower feelings of
hunger, a lower desire to eat, and significantly higher levels of fullness
within 15 minutes, for over two hours after consumption. This is one of four
studies which have consistently shown SlimBiome® reduces hunger and food
cravings leading to users both reducing the amount of food and changing the
type of food they eat, to less calorie intense food leading to sustainable
weight management. This suggests that SlimBiome® can be used as a natural
alternative to the current anti-obesity drugs on the market.

 

These findings on the acute impact of one dose of SlimBiome® are consistent
with those of a previous first study, also carried out by Professor Adele
Costabile, published in the Journal of Functional Foods (November 2020) which
showed that volunteers taking SlimBiome® for four weeks experienced a 21%
reduction in cravings for sweet foods and a 30% reduction in cravings for
savoury foods.

 

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "We're delighted to
see these study results which continue to prove the efficacy of Slimbiome® to
reduce hunger and food cravings which changes the amount and type of food
people eat leading to sustainable weight management. The current anti-obesity
drugs available on the market are not suitable for everyone, and Slimbiome®
represents a natural alternative that can be widely used with no adverse side
effects. Whilst using different mechanisms of action, SlimBiome(®) and
anti-obesity drugs work in a similar way by regulating insulin response and
promoting the feelings of fullness by slowing down stomach emptying."

 

SlimBiome® is available here (https://optibiotix.online/collections/all) in
sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars,
gummies, and soups/porridges and is increasingly being used by major sports
nutrition brands to support lean body development.

 

For the full press release issued by the University of Roehampton, see below.

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive
 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Roehampton University studies suggest a natural alternative to anti-obesity
drugs

 

The latest results from human studies reinforce findings that a mineral
enriched prebiotic fibre complex can help reduce hunger by 27% and support the
feeling of fullness by 35% offering a rapid and natural solution for those
seeking support in weight management.

 

The latest results from a study conducted by Professor Adele Costabile at the
University of Roehampton using Optibitix's SlimBiome® saw 20 volunteers given
50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes,
awaiting publication, suggested SlimBiome® intake had a significant impact on
insulin response combined with significantly lower feelings of hunger, a lower
desire to eat, and significantly higher levels of fullness for over two hours
after consumption.

 

These findings on the acute impact of one dose of SlimBiome are consistent
with those of a previous first study, also carried out by Professor Adele and
her team, published in the Journal of Functional Foods (November 2020) which
showed that taking SlimBiome® for four weeks volunteers experienced a 21%
reduction in cravings for sweet foods and a 30% reduction in cravings for
savoury foods.

 

Overall, 90% of volunteers lost weight and all volunteers reported a reduction
in waist and hip circumference and lost body fat. In addition, volunteers
improved their mood by 26%, suggesting they were losing weight without feeling
hungry or craving for food making it more sustainable. The results also
showed a significant change in volunteers gut microbiome with a statistically
significant increase in microbes associated with a lean body.

 

A report in November 2023 from J.P. Morgan Research forecast the
anti-obesity drug market will exceed $100 bn by 2030. However,
manufacturers and regulatory agencies report a number of common adverse
effects including nausea, diarrhoea, stomach pain, vomiting and constipation.
These possible side effects suggest they may not be suitable for all.

 

These studies suggest that a natural ingredient like SlimBiome(®), which was
tolerated well in all studies, may offer a natural approach to managing hunger
and food cravings to support weight management. Whilst using different
mechanisms of action, SlimBiome(®) and anti-obesity drugs work in a similar
way by regulating insulin response and promoting the feelings of fullness by
slowing down stomach emptying.

 

Professor Adele Costabile of the University of Roehampton commented: "Our
studies show a mineral enriched prebiotic fibre complex called SlimBiome can
reduce hunger and food cravings providing a natural and safe alternative to
anti- obesity drugs.  Most diets rely on a person's self-control to restrict
calories and, consequently, have a high failure rate.  This new approach to
weight loss suggests that controlling appetite can help reduce calorie intake
and improve the likelihood of success.  We are proud Roehampton is at the
forefront of this scientific revolution in weight management."

 

Co-investigator of the studies Dr. Michael Patterson of the University of
Roehampton said: "Recent anti-obesity drugs mimicking appetite supressing gut
hormones are an important advance in the treatment of obesity,but are not
suitable for all. Prebiotics like Slimbiome represent an exciting alternative,
and we think they increase secretion of your natural gut hormones and this
contributes to the suppression of hunger we observe with Slimbiome."

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLMATMTMBBLI